VAD Magnetic Levitation Rotor Thrombosis Mitigation 2026
VAD Maglev Rotor Thrombosis Mitigation 2026
Magnetic levitation eliminates mechanical bearing heat spots that seed thrombus in continuous-flow blood pumps. This dataset maps four technology clusters from CFD simulation to SLIC coatings and device-integrated sonothrombolysis.
Maglev VAD Thrombosis Mitigation: Field at a Glance
Ventricular assist devices employing magnetic levitation rotor technology eliminate mechanical bearings, removing the primary heat-generation sites that trigger protein adsorption and thrombus nucleation in continuous-flow blood pumps. The MOMENTUM 3 randomized clinical trial established the magnetically levitated HeartMate 3 as a clinical benchmark, demonstrating superior thrombotic outcomes versus axial-flow devices.
Among implanted LVADs, 4–9% experience thrombosis within one year. When a clot dislodges it can occlude blood vessels in vital organs, causing ischemic stroke or device failure. This clinical imperative drives four distinct engineering and clinical response clusters: maglev bearing architecture, antithrombotic surface coatings, computational fluid dynamics design tools, and interventional monitoring frameworks.
The most recent filings from Baylor College of Medicine (WO 2024, AU 2025) integrate SLIC hydrophilic coatings at high-shear components, stented inlet geometry to eliminate flow stasis pockets, flexible rotor design, and wireless power transfer into a unified LVAD architecture. Wireless charging also eliminates the driveline infection pathway that can indirectly modulate coagulation status.
In this dataset, innovation spans from 2013 case reports to 2026 patent filings, with the 2019–2024 period most densely populated by mechanistic innovation. Three identified patent assignees in retrieved records — Baylor College of Medicine, Academic Pharmaceuticals Incorporated, and MacMahon — reflect a field where much foundational IP may reside in larger device company portfolios not captured in this dataset.
Innovation Timeline and Cluster Activity in Retrieved Records
The dataset spans 2013 case reports through 2026 patent filings, with the 2019–2024 period most densely populated by mechanistic innovation across CFD simulation, coating engineering, and interventional thrombolysis.
Records by Technology Cluster and Assignee Type (Dataset Snapshot)
Coating Engineering and CFD/DTE are the most represented clusters in this dataset, with Baylor College of Medicine accounting for both identified patent filings in the antithrombotic coating cluster in retrieved records.
↗ Click bars to explorePublication Year Distribution of Retrieved Records (2013–2026)
The 2019–2022 period shows the highest concentration of retrieved records in this dataset, with CFD validation (2019), sonothrombolysis (2022), and combined monitoring frameworks (2022) marking key publication milestones.
↗ Click bars to exploreKey Clinical and Engineering Application Zones for VAD Thrombosis Mitigation
VAD maglev thrombosis mitigation technology addresses four distinct application domains documented in this dataset: advanced heart failure destination therapy and bridge-to-transplant, biventricular support systems, early warning hemodynamic monitoring, and non-blood-contacting epicardial assist architectures.
Bridge-to-Transplant and Destination Therapy
The MOMENTUM 3 randomized clinical trial established the magnetically levitated HeartMate 3 as a benchmark for thrombosis outcomes in bridge-to-transplant and destination therapy populations. The HM3’s full maglev design produced significantly reduced pump thrombosis rates versus axial-flow HeartMate II. Maglev architecture’s reduced thrombotic profile enables the longer implant durations required for destination therapy use.
Advanced Heart FailureBiventricular Support Systems
Thrombosis risk extends to right ventricular assist devices, as documented in a 2020 case report of recurrent pump thrombosis in bilateral HeartWare HVAD configuration. Right heart failure affecting 28–34% of LVAD patients — per MOMENTUM 3 data cited in a 2026 US patent — creates hemodynamic stasis conditions that promote secondary thrombosis in right-sided circuits. Adjacent IP from MacMahon (2026 US patent) addresses epicardial right heart support during LVAD procedures.
Biventricular SupportEarly Warning Hemodynamic Monitoring
Academic Pharmaceuticals Incorporated’s 2013 US patent describes a thrombosis warning system using an energy source and rheology sensor to detect potential thrombus formation in VAD patients. By 2022, combined echocardiographic flow velocity and digital pump logfile monitoring was formalized for HVAD thrombosis detection and management, enabling timely thrombolysis without surgical pump exchange. This monitoring paradigm is expected to evolve toward automated AI-driven early warning systems.
Hemodynamic MonitoringNon-Blood-Contacting Epicardial Assist
Magnetically active cardiac patches (MACPs) attached to the epicardial surface provide pulsatile cardiac assist without any blood-contacting components, eliminating blood-surface contact thrombosis entirely. Published in 2020, this approach is described as an untethered, non-blood-contacting ventricular assist device at proof-of-concept stage. The architectural direction may gain relevance as epicardial patch actuation materials science matures.
Epicardial AssistKey Patent Assignees in VAD Maglev Thrombosis Mitigation (Retrieved Records)
In this dataset, dedicated VAD thrombosis mitigation patent filings are concentrated among a small number of assignees in retrieved records. Baylor College of Medicine holds two retrieved patent filings (WO 2024, AU 2025) for the centrifugal LVAD with SLIC coating, making it the most active identifiable patent assignee in this specific niche in this dataset.
Patent Filings by Named Assignee — VAD Thrombosis Mitigation (Dataset Snapshot)
↗ Click bars to exploreBaylor College of Medicine
Baylor College of Medicine holds 2 retrieved patent filings in this dataset, a WO filing published December 2024 and an AU filing published December 2025, both covering a centrifugal LVAD integrating magnetic-based drive and bearing components, antithrombotic SLIC (slippery liquid-infused covalent) coatings at high-shear components, a stented inlet member to reduce flow stasis, flexible rotor design, and wireless power transfer. Both filings are pending status, indicating active international prosecution strategy across PCT and Australian jurisdictions.
United StatesAcademic Pharmaceuticals Incorporated
Academic Pharmaceuticals Incorporated holds 1 retrieved patent filing in this dataset — a 2013 US patent for a thrombosis warning system that uses an energy source and rheology sensor to detect potential thrombus formation in VAD patients. This filing represents an early signal of the monitoring paradigm that later evolved into combined echocardiographic and digital-logfile approaches. The patent is filed in the United States jurisdiction.
United StatesNext-Generation Signals in VAD Thrombosis Mitigation (2022–2026)
The most recent filings and publications in this dataset signal four directional shifts: multi-modal design integration, device-integrated interventional thrombolysis, non-blood-contacting epicardial architectures, and AI-augmented digital monitoring frameworks.
Multi-Modal Integration: SLIC + MagLev + Wireless Power
The Baylor College of Medicine WO/AU filings (2024–2025) represent the clearest leading-edge signal in this dataset, combining SLIC hydrophilic coatings at high-shear components with magnetic bearing and drive, stented inlet geometry to eliminate flow stasis, flexible rotor design, and wireless power transfer in a unified LVAD architecture. Wireless charging also removes the driveline infection pathway that can indirectly modulate coagulation status and systemic inflammation. This multi-modal approach treats thrombosis risk at the bearing, surface, geometry, and infection vector levels simultaneously.
Device-Integrated Sonothrombolysis
The 2022 interventional sonothrombolysis study demonstrated ultrasound transducer rings mounted directly on the LVAD shell, with drug-loaded microbubbles injected interventionally to dissolve pump thrombus in 30 minutes in a live sheep model without device or organ damage. This approach shifts from purely systemic pharmacotherapy toward locally applied physical dissolution, representing device-native thrombus management capability. If clinically validated, it could reduce event-fatality rates and extend device functional life.
Maglev Architecture vs. Axial-Flow Bearing Design: Thrombosis Profile
Click any row to explore further.
| Dimension | Maglev (HeartMate 3) | Axial-Flow Bearing (HeartMate II) |
|---|---|---|
| Bearing Type | Full magnetic levitation — no mechanical contact | Mechanical contact bearings with heat-generating friction |
| Thrombus Nucleation Sites | Heat spots from mechanical bearings eliminated | Mechanical bearing heat spots are primary thrombus nucleation sites per literature |
| Clinical Thrombosis Outcome | Superior thrombotic endpoints per MOMENTUM 3 RCT (2020) | Recurrent pump thrombosis cases reported 2013; inferior to HM3 in MOMENTUM 3 |
| CFD Simulation Evidence | Rotor washout patterns reduce stagnant zone residence time | Thrombus accumulation increases with decreased flow rate (CFD, 2016) |
| Surface Coating Compatibility | Compatible with SLIC hydrophilic coatings at high-shear rotor components (Baylor, 2024–2025) | Surface chemistry improvement can suppress thrombus per 2016 CFD study |
| Right Heart Failure Risk | 28–34% of patients affected per MOMENTUM 3 data cited in 2026 US patent | Comparable right heart failure rates in continuous-flow device population |
| Wireless Power Compatibility | Baylor WO/AU 2024–2025 filings integrate wireless power transfer, eliminating driveline | Driveline retained; infection pathway remains active |
Frequently Asked Questions: VAD Maglev Rotor Thrombosis Mitigation
According to the literature in this dataset, 4–9% of implanted LVADs experience thrombosis within one year. When a clot dislodges it can occlude blood vessels in vital organs, causing ischemic stroke or device failure.
Maglev rotors eliminate the mechanical contact bearings that generate heat spots described in the literature as primary thrombus nucleation sites. Maglev design also creates uniform hydrodynamic clearances enabling rotor washout patterns that reduce blood residence time in stagnant zones adjacent to the impeller, suppressing thrombus formation.
SLIC stands for slippery liquid-infused covalent coating — a hydrophilic antithrombotic surface treatment applied at high-shear components such as the rotor. The Baylor College of Medicine WO (2024) and AU (2025) patents integrate SLIC coatings into a centrifugal LVAD architecture alongside magnetic bearing/drive, stented inlet geometry, flexible rotor, and wireless power transfer.
Device Thrombogenicity Emulation is an in silico and in vitro framework that predicts VAD thrombogenicity by simulating platelet activation under flow-induced stresses to generate a quantitative Thrombogenic Footprint for each design iteration. It was validated in vivo in calf models in 2019, providing a regulatory-relevant design qualification pathway for iterative rotor geometry and gap clearance optimization.
The 2022 sonothrombolysis study demonstrated ultrasound transducer rings mounted directly on the LVAD shell. Drug-loaded microbubbles are injected interventionally and activated by the transducer rings to dissolve pump thrombus. In a live sheep model, this approach dissolved thrombus in 30 minutes without device or organ damage, shifting from systemic pharmacotherapy toward locally applied physical dissolution.
Wireless power transfer eliminates the LVAD driveline, which removes a parallel infection pathway. The Baylor College of Medicine filings and the strategic implications section in this dataset note that driveline elimination removes the associated systemic inflammatory response that can modulate coagulation status — making wireless charging a functional antithrombotic co-feature, not merely a convenience element.
Data and insights on this page are based on a limited patent and literature dataset and are for reference only. Figures may not represent the complete technology landscape.